Michelle C. Miller

6.8k total citations · 1 hit paper
71 papers, 2.2k citations indexed

About

Michelle C. Miller is a scholar working on Molecular Biology, Immunology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Michelle C. Miller has authored 71 papers receiving a total of 2.2k indexed citations (citations by other indexed papers that have themselves been cited), including 35 papers in Molecular Biology, 30 papers in Immunology and 28 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Michelle C. Miller's work include Galectins and Cancer Biology (29 papers), Advanced Breast Cancer Therapies (28 papers) and Glycosylation and Glycoproteins Research (20 papers). Michelle C. Miller is often cited by papers focused on Galectins and Cancer Biology (29 papers), Advanced Breast Cancer Therapies (28 papers) and Glycosylation and Glycoproteins Research (20 papers). Michelle C. Miller collaborates with scholars based in United States, Germany and Spain. Michelle C. Miller's co-authors include Kevin H. Mayo, Anatole A. Klyosov, Ruud P.M. Dings, Pierfranco Conté, Mario Campone, Irina V. Nesmelova, Hans‐Joachim Gabius, Sibylle Loibl, Hope S. Rugo and Ingrid A. Mayer and has published in prestigious journals such as Proceedings of the National Academy of Sciences, American Journal of Clinical Nutrition and Cancer Research.

In The Last Decade

Michelle C. Miller

69 papers receiving 2.2k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Alpelisib plus fulvestrant for PIK3CA-mutated, hormone receptor-positive, human epidermal growth factor receptor-2–negative advanced breast cancer: final overall survival results from SOLAR-1

2020 371 citations Fabrice André, Eva Ciruelos et al. Annals of Oncology profile →

Peers

Countries citing papers authored by Michelle C. Miller

Since Specialization

Citations

This map shows the geographic impact of Michelle C. Miller's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Michelle C. Miller with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Michelle C. Miller more than expected).

Fields of papers citing papers by Michelle C. Miller

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Michelle C. Miller. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Michelle C. Miller. The network helps show where Michelle C. Miller may publish in the future.

Co-authorship network of co-authors of Michelle C. Miller

This figure shows the co-authorship network connecting the top 25 collaborators of Michelle C. Miller. A scholar is included among the top collaborators of Michelle C. Miller based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Michelle C. Miller. Michelle C. Miller is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	The X-ray Structures of [Fe(CO)3(η4-6-exo-(PAr3)cyclohepta-2,4-dien-1-one][BF4] (Ar = m-C6H4CH3 or p-C6H4F) 2024 ·Journal of Chemical Crystallography ·Michelle C. Miller, (unknown), (unknown), (unknown), Chip Nataro	0
2	77 JNJ-77242113 treatment induces strong systemic pharmacodynamic response versus placebo in patients with plaque psoriasis: Results from the phase 2, FRONTIER 1 study 2023 ·Journal of Investigative Dermatology ·Andreas Pinter, Kilian Eyerich, Amy S. Paller, Arun Kannan, (unknown), Diane Horowitz, Sunita Bhagat, Donald Richards, (unknown), Bradford L. McRae, Ya‐Wen Yang, Michelle C. Miller, Cynthia Marie Carver DeKlotz, Robert Bissonnette	1
3	Isomerization of proline-46 in the N-terminal tail of galectin-3 enhances T cell apoptosis via the ROS-ERK pathway 2023 ·International Journal of Biological Macromolecules ·(unknown), Menghui Wang, Michelle C. Miller, Zhen He, Xuejiao Xu, Yifa Zhou, Kevin H. Mayo, Guihua Tai	1
4	Justifying Ribociclib Dose in Patients with Advanced Breast Cancer with Renal Impairment Based on PK, Safety, and Efficacy Data: An Innovative Approach Integrating Data from a Dedicated Renal Impairment Study and Oncology Clinical Trials 2023 ·Clinical Pharmacokinetics ·Yan Ji, (unknown), Michelle Quinlan, Paolo Serra, Yingbo Wang, Abhijit Chakraborty, Michelle C. Miller	6
5	Molecular basis for cellular retinoic acid-binding protein 1 in modulating CaMKII activation 2023 ·Frontiers in Molecular Biosciences ·(unknown), Michelle C. Miller, (unknown), Kevin H. Mayo, Li‐Na Wei	3
6	Galectin-3 N-terminal tail prolines modulate cell activity and glycan-mediated oligomerization/phase separation 2021 ·Proceedings of the National Academy of Sciences ·(unknown), Xuejiao Xu, Hairong Cheng, Michelle C. Miller, Zhen He, (unknown), Zhongyu Zhang, Avraham Raz, Kevin H. Mayo, Guihua Tai, Yifa Zhou	39
7	Time course and management of key adverse events during the randomized phase III SOLAR-1 study of PI3K inhibitor alpelisib plus fulvestrant in patients with HR-positive advanced breast cancer 2020 ·Annals of Oncology ·Hope S. Rugo, Fabrice André, Toshinari Yamashita, (unknown), I. Toledano, Salomon M. Stemmer, Josefina Cruz Jurado, Dejan Juric, Ingrid A. Mayer, Eva Ciruelos, Hiroji Iwata, Pierfranco Conté, Mario Campone, C. Wilke, David Mills, Agnes Lteif, Michelle C. Miller, (unknown), Sibylle Loibl	113
8	LBA18 Overall survival (os) results from SOLAR-1, a phase III study of alpelisib (ALP) + fulvestrant (FUL) for hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2–) advanced breast cancer (ABC) 2020 ·Annals of Oncology ·Fabrice André, Eva Ciruelos, Dejan Juric, Sibylle Loibl, Mario Campone, Ingrid A. Mayer, Gábor Rubovszky, Toshinari Yamashita, Bella Kaufman, Yen‐Shen Lu, Kenichi Inoue, Zsuzsanna Pápai, Masato Takahashi, Farhat Ghaznawi, David Mills, Mathilde Kaper, Michelle C. Miller, Pierfranco Conté, Hiroji Iwata, Hope S. Rugo	16
9	Structural insight into the binding of human galectins to corneal keratan sulfate, its desulfated form and related saccharides 2020 ·Scientific Reports ·Michelle C. Miller, Chao Cai, Kanin Wichapong, (unknown), Nicola L. B. Pohl, Robert J. Linhardt, Hans‐Joachim Gabius, Kevin H. Mayo	16
10	Ribociclib with letrozole vs letrozole alone in elderly patients with hormone receptor-positive, HER2-negative breast cancer in the randomized MONALEESA-2 trial 2017 ·Breast Cancer Research and Treatment ·Gabe S. Sonke, Lowell L. Hart, Mario Campone, Frans Erdkamp, Wolfgang Janni, Sunil Verma, Cristian Villanueva, Erik Jakobsen, Emilio Alba, Erik Wist, Anne Favret, Thomas Bachelot, Roberto Hegg, Paul Wheatley‐Price, Farida Souami, Santosh Sutradhar, Michelle C. Miller, Caroline Germa, Howard A. Burris	61
11	Discovery and development of novel therapies in advanced breast cancer: rapid development of ribociclib 2017 ·Annals of Oncology ·Caroline Germa, Michelle C. Miller, Pabak Mukhopadhyay, Becker Hewes, Giordano Caponigro, Stefan Scherer, Samit Hirawat	6
12	Updated results from MONALEESA-2, a phase 3 trial of first-line ribociclib + letrozole in hormone receptor-positive (HR+), HER2-negative (HER2–) advanced breast cancer (ABC) 2017 ·Annals of Oncology ·Simon Spazzapan, Pierfranco Conté, Edda Simoncini, Mario Campone, Michelle C. Miller, Gabe S. Sonke	1
13	Intra- and intermolecular interactions of human galectin-3: assessment by full-assignment-based NMR 2016 ·Glycobiology ·Hans Ippel, Michelle C. Miller, Sabine Vértesy, Yi Zheng, F. Javier Cañada, Dennis Suylen, Kimiko Umemoto, (unknown), Tilman M. Hackeng, Guihua Tai, Hakon Leffler, Jürgen Kopitz, Sabine André, Hans-Dieter Kübler, Jesús Jiménez‐Barbero, Stefan Oscarson, Hans‐Joachim Gabius, Kevin H. Mayo	64
14	Binding of polysaccharides to human galectin-3 at a noncanonical site in its carbohydrate recognition domain 2015 ·Glycobiology ·Michelle C. Miller, Hans Ippel, Dennis Suylen, Anatole A. Klyosov, Peter G. Traber, Tilman M. Hackeng, Kevin H. Mayo	58
15	Defining the Potential of Aglycone Modifications for Affinity/Selectivity Enhancement against Medically Relevant Lectins: Synthesis, Activity Screening, and HSQC‐Based NMR Analysis 2014 ·ChemBioChem ·(unknown), Tze Chieh Shiao, Sabine André, Michelle C. Miller, (unknown), Kevin H. Mayo, Hans‐Joachim Gabius, René Roy	17
16	Structure-Based Optimization of Angiostatic Agent 6DBF7, an Allosteric Antagonist of Galectin-1 2012 ·Journal of Pharmacology and Experimental Therapeutics ·Ruud P.M. Dings, (unknown), Michelle C. Miller, Melissa Loren, (unknown), Thomas R. Hoye, Kevin H. Mayo	37
17	Structural features for α-galactomannan binding to galectin-1 2011 ·Glycobiology ·Michelle C. Miller, Anatole A. Klyosov, Kevin H. Mayo	25
18	Structural aspects of binding of α-linked digalactosides to human galectin-1 2011 ·Glycobiology ·Michelle C. Miller, João P. Ribeiro, (unknown), Sonsoles Martín‐Santamaría, F. Javier Cañada, Irina V. Nesmelova, Sabine André, Mabel Pang, Anatole A. Klyosov, Linda G. Baum, Jesús Jiménez‐Barbero, Hans‐Joachim Gabius, Kevin H. Mayo	40
19	Using pulse field gradient NMR diffusion measurements to define molecular size distributions in glycan preparations 2009 ·Carbohydrate Research ·Michelle C. Miller, Anatole A. Klyosov, (unknown), Kevin H. Mayo	24
20	The -galactomannan Davanat binds galectin-1 at a site different from the conventional galectin carbohydrate binding domain 2009 ·Glycobiology ·Michelle C. Miller, Anatole A. Klyosov, Kevin H. Mayo	71

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Yongsheng Wang Breakdown of academic impact, for papers by Roberta Frapolli Breakdown of academic impact, for papers by An Wouters Breakdown of academic impact, for papers by Arun Satelli Breakdown of academic impact, for papers by Anna Scuto Breakdown of academic impact, for papers by Suimin Qiu Breakdown of academic impact, for papers by Kajsa Paulsson Breakdown of academic impact, for papers by Timothy F. Burns